--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Puchheim/Düsseldorf, 29 June 2009 (euro adhoc) - Multinational consumer
chemicals company Henkel will use Sloning BioTechnology´s proprietary protein
engineering platform in their Laundry and Home Care enzyme development.
The two companies announced that a first project has been launched involving
SlonoMax mutant libraries as part of a development process aiming at the
functional optimisation of a specific enzyme.
Enzymes constitute an important ingredient in many modern household chemicals;
their constant improvement is crucial to Henkel. Directed Evolution processes
are used to optimise their properties. "In the past, we would generate huge
collections of genetic variants of promising enzymes and screen them for desired
features. With Sloning´s technology, we obtain libraries that precisely follow
our design and contain all desired mutants. We expect to considerably increase
our success rate and shorten development time", says Karl-Heinz Maurer, Director
Research and Development of Henkel´s Laundry and Home Care division.
Sloning´s CEO Heinz Schwer explains: "Our genetic engineering platform allows to
introduce selected alternative codons, leading to only those mutations the
scientist actually wanted. This gives researchers additional freedom in setting
up their experiments. We are happy to count Henkel among our customers. This
underscores the added value SlonoMax libraries provide to any directed evolution
process."
About Sloning
Sloning BioTechnology GmbH specializes in the production of highly diverse and
precisely engineered gene libraries. Sloning´s superior genetic libraries are
essential in screening for new and improved therapeutic or industrial proteins.
At the heart is its core technology, Slonomics®, a patented genetic engineering
platform using sets of double stranded DNA triplets. Sloning is an investment
holding of the listed venture capital company Deutsche Effecten- und
Wechsel-Beteiligungsgesellschaft AG (DEWB).
About Henkel
Headquartered in Düsseldorf / Germany, Henkel KGaA has about 55,000 employees
worldwide and counts among the most internationally aligned German-based
companies in the global marketplace. People in approximately 125 countries
around the world trust in brands and technologies from Henkel.
CONTACT:
Sloning Headquarter
Dr. Heinz Schwer, CEO
+49 89 80 90 95 - 0
h.schwer@sloning.com
or
Sloning North America
Garry Merry, Business Development
1 510-287-6600
g.merry@sloning.com
Further inquiry note:
Marco Scheidler
DEWB AG
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
emitter: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Leutragraben 1
D-07743 Jena
phone: +49 (0)3641 573 3600
FAX: +49 (0)3641 573 3610
mail: ir@dewb-vc.com
WWW: http://www.dewb-vc.com
sector: Financial & Business Services
ISIN: DE0008041005
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Stuttgart, München
language: English
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE
